- Home
- NMRA vs OABI Comparison
NMRA vs OABI Comparison
Compare NMRA & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- OABI
- Stock Information
- Founded
- NMRA 2019
- OABI 2012
- Country
- NMRA United States
- OABI United States
- Employees
- NMRA N/A
- OABI N/A
- Industry
- NMRA
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- OABI Health Care
- Exchange
- NMRA Nasdaq
- OABI Nasdaq
- Market Cap
- NMRA 268.5M
- OABI 240.5M
- IPO Year
- NMRA 2023
- OABI N/A
- Fundamental
- Price
- NMRA $1.62
- OABI $1.85
- Analyst Decision
- NMRA Buy
- OABI Strong Buy
- Analyst Count
- NMRA 8
- OABI 3
- Target Price
- NMRA $7.14
- OABI $6.67
- AVG Volume (30 Days)
- NMRA 931.0K
- OABI 498.7K
- Earning Date
- NMRA 08-06-2025
- OABI 08-06-2025
- Dividend Yield
- NMRA N/A
- OABI N/A
- EPS Growth
- NMRA N/A
- OABI N/A
- EPS
- NMRA N/A
- OABI N/A
- Revenue
- NMRA N/A
- OABI $23,027,000.00
- Revenue This Year
- NMRA N/A
- OABI N/A
- Revenue Next Year
- NMRA N/A
- OABI $45.02
- P/E Ratio
- NMRA N/A
- OABI N/A
- Revenue Growth
- NMRA N/A
- OABI 6.05
- 52 Week Low
- NMRA $0.61
- OABI $1.22
- 52 Week High
- NMRA $17.19
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- NMRA 51.72
- OABI 43.65
- Support Level
- NMRA $1.56
- OABI $1.74
- Resistance Level
- NMRA $1.78
- OABI $2.09
- Average True Range (ATR)
- NMRA 0.12
- OABI 0.12
- MACD
- NMRA -0.03
- OABI -0.02
- Stochastic Oscillator
- NMRA 58.97
- OABI 40.74
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.